GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Abionyx Pharma (LTS:0RAG) » Definitions » ROA %

Abionyx Pharma (LTS:0RAG) ROA % : -17.72% (As of Dec. 2023)


View and export this data going back to 2015. Start your Free Trial

What is Abionyx Pharma ROA %?

ROA % is calculated as Net Income divided by its average Total Assets over a certain period of time. Abionyx Pharma's annualized Net Income for the quarter that ended in Dec. 2023 was €-2.54 Mil. Abionyx Pharma's average Total Assets over the quarter that ended in Dec. 2023 was €14.33 Mil. Therefore, Abionyx Pharma's annualized ROA % for the quarter that ended in Dec. 2023 was -17.72%.

The historical rank and industry rank for Abionyx Pharma's ROA % or its related term are showing as below:

LTS:0RAG' s ROA % Range Over the Past 10 Years
Min: -66.17   Med: -29.6   Max: 15.81
Current: -23.72

During the past 11 years, Abionyx Pharma's highest ROA % was 15.81%. The lowest was -66.17%. And the median was -29.60%.

LTS:0RAG's ROA % is ranked better than
61.24% of 1548 companies
in the Biotechnology industry
Industry Median: -34.485 vs LTS:0RAG: -23.72

Abionyx Pharma ROA % Historical Data

The historical data trend for Abionyx Pharma's ROA % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Abionyx Pharma ROA % Chart

Abionyx Pharma Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
ROA %
Get a 7-Day Free Trial Premium Member Only Premium Member Only 15.81 -18.37 -36.25 -22.34 -22.95

Abionyx Pharma Semi-Annual Data
Jun14 Dec14 Jun15 Dec15 Jun16 Dec16 Jun17 Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23
ROA % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -45.16 -25.49 -19.48 -30.32 -17.72

Competitive Comparison of Abionyx Pharma's ROA %

For the Biotechnology subindustry, Abionyx Pharma's ROA %, along with its competitors' market caps and ROA % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Abionyx Pharma's ROA % Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Abionyx Pharma's ROA % distribution charts can be found below:

* The bar in red indicates where Abionyx Pharma's ROA % falls into.



Abionyx Pharma ROA % Calculation

Abionyx Pharma's annualized ROA % for the fiscal year that ended in Dec. 2023 is calculated as:

ROA %=Net Income (A: Dec. 2023 )/( (Total Assets (A: Dec. 2022 )+Total Assets (A: Dec. 2023 ))/ count )
=-3.518/( (15.823+14.834)/ 2 )
=-3.518/15.3285
=-22.95 %

Abionyx Pharma's annualized ROA % for the quarter that ended in Dec. 2023 is calculated as:

ROA %=Net Income (Q: Dec. 2023 )/( (Total Assets (Q: Jun. 2023 )+Total Assets (Q: Dec. 2023 ))/ count )
=-2.54/( (13.832+14.834)/ 2 )
=-2.54/14.333
=-17.72 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

In the calculation of annual ROA %, the net income of the last fiscal year and the average total assets over the fiscal year are used. In calculating the quarterly data, the Net Income data used here is two times the semi-annual (Dec. 2023) net income data. ROA % is displayed in the 30-year financial page.


Abionyx Pharma  (LTS:0RAG) ROA % Explanation

ROA % measures the rate of return on the total assets (shareholder equity plus liabilities). It measures a firm's efficiency at generating profits from shareholders' equity plus its liabilities. ROA % shows how well a company uses what it has to generate earnings. ROA %s can vary drastically across industries. Therefore, ROA % should not be used to compare companies in different industries. For retailers, a ROA % of higher than 5% is expected. For example, Wal-Mart (WMT) has a ROA % of about 8% as of 2012. For banks, ROA % is close to their interest spread. A bank’s ROA % is typically well under 2%.

Similar to ROE, ROA % is affected by profit margins and asset turnover. This can be seen from the Du Pont Formula:

ROA %(Q: Dec. 2023 )
=Net Income/Total Assets
=-2.54/14.333
=(Net Income / Revenue)*(Revenue / Total Assets)
=(-2.54 / 5.024)*(5.024 / 14.333)
=Net Margin %*Asset Turnover
=-50.56 %*0.3505
=-17.72 %

Note: The Net Income data used here is two times the semi-annual (Dec. 2023) net income data. The Revenue data used here is two times the semi-annual (Dec. 2023) revenue data.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Be Aware

Like ROE, ROA % is calculated with only 12 months data. Fluctuations in the company's earnings or business cycles can affect the ratio drastically. It is important to look at the ratio from a long term perspective. ROA % can be affected by events such as stock buyback or issuance, and by goodwill, a company's tax rate and its interest payment. ROA % may not reflect the true earning power of the assets. A more accurate measurement is ROC % (ROC).

Many analysts argue the higher return the better. Buffett states that really high ROA % may indicate vulnerability in the durability of the competitive advantage.

E.g. Raising $43b to take on KO is impossible, but $1.7b to take on Moody's is. Although Moody's ROA % and underlying economics is far superior to Coca Cola, the durability is far weaker because of lower entry cost.


Abionyx Pharma ROA % Related Terms

Thank you for viewing the detailed overview of Abionyx Pharma's ROA % provided by GuruFocus.com. Please click on the following links to see related term pages.


Abionyx Pharma (LTS:0RAG) Business Description

Traded in Other Exchanges
Address
33-43 Avenue Georges Pompidou-Bat D2, Balma, FRA, 31130
Abionyx Pharma is a new generation biotech company dedicated to the discovery and development of innovative therapies for patients without existing or effective treatment. The biotech assets inherited from CERENIS Therapeutics constitute a portfolio of valuable programs for the treatment of cardiovascular diseases and associated metabolic diseases such as NAFLD and NASH as well as an HDL targeted drug delivery platform in oncology, more specifically in Immuno oncology and chemotherapy.

Abionyx Pharma (LTS:0RAG) Headlines

No Headlines